Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) Grows on 8-K Filing, General Optimism

Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) is going into the mainstream, with more than a week of steadily climbing buying, and a gain to 75 cents. Dollar volumes peaked at $2.83 million, and the ticker added 36.36% on the day. The activity directly followed an 8-K filing for changes in bylaws and fiscal year end, relatively minor events, which however amplified the effect that had been building up in the past day.

And according to analysts, BZNE is a small but extremely promising pharmaceutical company that may be in for a great future of licensing its technological breakthrough.

On October 10th, BZNE prepared for the future by authorizing a further 200 million shares of common stock and 5 million preferred shares. This doubles the amount of common shares authorized. The company is still running with less than 70 million shares, and a market cap grown to around $52 million.

Opinions on BZNE, which was previously barely traded, show a cautious optimism, mixed with the feeling that something wrong is going on with the company, with potential stock dilution and large inside holdings. At the same time, BZNE received a glowing review from The Street analysts, of course with warnings that early-stage biotechs are risky.

But the biggest booster behind BZNE is the backing of Dr. Philip Frost, and his Opko Health, a large and growing company reaching out to numerous biotech pathways, and already valued at $4 billion. It speaks volumes that BZNE is now a part of that portfolio. Speaking of portfolios, BZNE has the ownership of the QuSome technology, and a few potential uses for it, in cosmetics as well as in food supplementation.

While BZNE may be an exception that will yet prove itself, the biotech sector remains active among the most traded penny stocks, with enough companies supported by innovation and marketing potential. Right now, Titan Pharmaceuticals, Inc. (OTCBB:TTNP) is making a recovery, though struggling a bit with the $1 levels. TTNP slid about 6% to 97 cents as activity was lowered in the past days.

And despite the choppy trading, AP Pharma, Inc. (OTCBB:APPA) has been making a recovery in October, breaking over 40 cents with a 15% gain on Tuesday. The ticker has been sliding for a while, and it remains to be seen if there will be another run up, or all will remain a dead cat bounce.

If you still want to join BZNE, keep in mind the inherent risk in unknown stocks. Although investors’ forums suggest that $1 could be a reasonable price, avoid putting into BZNE funds that you cannot afford to lose.